Funding for this research was provided by:
Public Health Agency of Canada (1617-HQ-000045)
Medical Psychiatry Alliance
Received: 19 August 2019
Accepted: 24 May 2020
First Online: 12 June 2020
Ethics approval and consent to participate
: Not Applicable.
: Not Applicable.
: All authors on this manuscript declare that they have no competing interest with respect to this rapid realist review. However, some authors have general disclosures to report: Peter Selby reports receiving grants and/or salary from Centre for Addiction and Mental Health, Ontario Ministry of Health and Long-Term care, CIHR, Canadian Centre on Substance Use and Addiction, Public Health Agency of Canada, Medical Psychiatry Alliance, Canadian Cancer Society Research Institute, Cancer Care Ontario, and the Ontario Institute for Cancer Research. Peter Selby also reports receiving funding from the following commercial organizations Pfizer Inc./Pfizer Canada, Bhasin Consulting Fund, Shoppers Drug Mart and Patient-Centered Outcomes Research Institute; and has received consulting fees from Pfizer Inc./Pfizer Canada, Johnson & Johnson Group of Companies, MedPlan Communications. Through an open tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which Peter Selby is the principal investigator or co-investigator. Heather Manson reports employment with Public Health Ontario, and academic appointment as assistant professor at the University of Toronto and adjunct professor at the University of Waterloo. Wayne deRuiter reports grant funding from Pfizer Inc. and Medical Psychiatry Alliance. Wayne deRuiter also reports stock ownership in Abbott Laboratories. The remaining authors, Nadia Minian, Tricia Corrin, Mathangee Lingam, Terri Rodak, Valerie H. Taylor, Rosa Dragonetti, Laurie Zawertailo, Osnat C. Melamed, and Margaret Hahn, declare that they have no disclosures to report.